Results 21 to 30 of about 18,680 (231)

Discovery of a Dual IDO1/TDO Inhibitor That Modulates Enzymatic Activity and IDO1/SHP-2 Signaling. [PDF]

J Med Chem
Rezzi SJ, Butticè A, Villani S, Lesca G, Rossini S, Panfili E, Mazzoletti D, Bari E, Violante D, Serafini M, Massarotti A, Orabona C, Pallotta MT, Aprile S, Fallarini S, Del Grosso E, Di Martino RMC, Miggiano R, Pirali T.   +18 more
europepmc   +2 more sources

Structure and Plasticity of Indoleamine 2,3-Dioxygenase 1 (IDO1)

, 2021
Since the discovery of the implication of indoleamine 2,3-dioxygenase 1 (IDO1) in tumoral immune resistance in 2003, the search for inhibitors has been intensely pursued both in academia and in pharmaceutical companies, supported by the publication of ...
Olivier Michielin, Vincent Zoete (25359), Vincent Zoete, Olivier Michielin (25362), Ute F. Röhrig (1716295), Ute F. Röhrig   +5 more
core   +2 more sources

IDO1 can impair NK cells function against non-small cell lung cancer by downregulation of NKG2D Ligand via ADAM10

Pharmacological Research, 2022
Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the rate-limiting step in tryptophan catabolism along the kynurenine (Kyn) pathway and exerts immunosuppressive properties mainly via activation of transcription factor aryl hydrocarbon receptor (AhR ...
Xin Fang, Leilei Guo, Zikang Xing, Lei Shi, Heng Liang, Aiying Li, Chunxiang Kuang, Bangbao Tao, Qing Yang   +8 more
doaj   +1 more source

IDO1 in cancer: a Gemini of immune checkpoints [PDF]

Cellular & Molecular Immunology, 2018
Indoleamine 2, 3-dioxygenase 1 (IDO1) is a rate-limiting metabolic enzyme that converts the essential amino acid tryptophan (Trp) into downstream catabolites known as kynurenines. Coincidently, numerous studies have demonstrated that IDO1 is highly expressed in multiple types of human cancer.
Lijie, Zhai, Erik, Ladomersky, Alicia, Lenzen, Brenda, Nguyen, Ricky, Patel, Kristen L, Lauing, Meijing, Wu, Derek A, Wainwright   +7 more
openaire   +2 more sources

On the Non-Redundant Roles of TDO2 and IDO1 [PDF]

Frontiers in Immunology, 2014
The Perspective by Pallotta et al. (1) offers the opportunity of a few more considerations on the mutually supportive relationship between tryptophan catabolic enzymes and the aryl hydrocarbon receptor (AhR) in the transitional response aimed at reinstalling homeostatic tolerance after meeting the needs of an acute inflammatory reaction (2).
openaire   +4 more sources

Targeting Indoleamine 2,3-Dioxygenase 1: Fighting Cancers via Dormancy Regulation

Frontiers in Immunology, 2021
The connection between indoleamine 2,3-dioxygenase 1 (IDO1) and tumour dormancy – a quiescent state of tumour cells which has been consistently linked to metastasis and cancer recurrence – is rarely discussed despite the pivotal role of IDO1 in cancer ...
Chao Yang, Chan-Tat Ng, Chan-Tat Ng, Dan Li, Lei Zhang, Lei Zhang   +5 more
doaj   +1 more source

Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer

Neoplasia: An International Journal for Oncology Research, 2023
Background: The enzyme indoleamine 2,3-dioxygenase 1 (IDO1) plays a crucial role in regulating the immune system's response to tumors, but its exact role in cancer, especially in high-grade serous ovarian cancer (HGSOC), remains controversial.
Inga Hoffmann, Mihnea P. Dragomir, Nanna Monjé, Carlotta Keunecke, Catarina Alisa Kunze, Simon Schallenberg, Sofya Marchenko, Wolfgang D. Schmitt, Hagen Kulbe, Jalid Sehouli, Ioana Elena Braicu, Paul Jank, Carsten Denkert, Silvia Darb-Esfahani, David Horst, Bruno V. Sinn, Christine Sers, Philip Bischoff, Eliane T. Taube   +18 more
doaj   +1 more source

Indoleamine 2, 3-dioxygenase 1 inhibitory compounds from natural sources

Frontiers in Pharmacology, 2022
L-tryptophan metabolism is involved in the regulation of many important physiological processes, such as, immune response, inflammation, and neuronal function.
Ying Tan, Miaomiao Liu, Ming Li, Yujuan Chen, Meng Ren   +4 more
doaj   +1 more source

Profiling targetable immune checkpoints in osteosarcoma

OncoImmunology, 2018
Osteosarcomas are aggressive bone tumors for which therapeutic advances have not improved over several decades. Unlike most pediatric tumors, the osteosarcoma genome is remarkably unstable, characterized by numerous copy number alterations and ...
Troy A McEachron, Timothy J Triche, Laurie Sorenson, David M Parham, John D Carpten   +4 more
doaj   +1 more source

GBP1 Facilitates Indoleamine 2,3-Dioxygenase Extracellular Secretion to Promote the Malignant Progression of Lung Cancer

Frontiers in Immunology, 2021
IDO1-mediated immune escape can lead to the malignant progression of tumors. However, the precise mechanism of IDO1 remains unclear. This study showed that IDO1 can bind to GBP1 and increase the extracellular secretion of IDO1 with the assistance of GBP1,
Yinnan Meng, Wei Wang, Meng Chen, Kuifei Chen, Xinhang Xia, Suna Zhou, Haihua Yang, Haihua Yang   +7 more
doaj   +1 more source